Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Status:
RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.

PHASE4

Mayo Clinic

ACE-011